Michelle Monje-Deisseroth, a renowned neuroscientist, has dedicated her career to understanding and treating the devastating childhood brain tumor known as diffuse intrinsic pontine gliomas (DIPG). These tumors, which wrap themselves around the brainstem, are notoriously difficult to treat, with most children not surviving beyond a year after diagnosis.
Over the years, Monje-Deisseroth has made significant strides in unraveling the mysteries of DIPG by developing cell and animal models to study its invasive nature. However, despite her scientific advancements, she found herself frustrated by the lack of effective treatment options for her patients. That all changed in June 2020 when she launched a groundbreaking clinical trial using engineered cells called CAR-Ts and targeting a previously unknown vulnerability on the surface of the tumor.
The results of the trial, which were recently published in Nature, are both promising and bittersweet. While nine out of the eleven patients ultimately succumbed to the disease, four patients experienced significant tumor shrinkage, offering a glimmer of hope in the fight against DIPG. One such patient, a 20-year-old named Drew, remains in complete remission an impressive 30 months after receiving the novel therapy.
The success of Monje-Deisseroth’s trial represents a major breakthrough in the field of pediatric oncology, offering new hope to families grappling with the devastating impact of DIPG. The use of CAR-T therapy and the identification of a specific vulnerability on the tumor surface have opened up new avenues for targeted treatment approaches, potentially changing the prognosis for children battling this aggressive cancer.
As the medical community continues to grapple with the complexities of DIPG, researchers like Monje-Deisseroth remain at the forefront of innovation, pushing the boundaries of what is possible in the fight against childhood brain tumors. Their tireless dedication and groundbreaking discoveries offer a ray of hope to patients and families facing the unimaginable challenges posed by these devastating diseases.
